drugset
drugset / Trial / NCT04311528

9-valent HPV Vaccine in Postpartum Women

NCT04311528 ↗

Phase 4 Unknown 100 enrolled Augusta University
NaSingle-groupOpen-labelPrevention

Summary

This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.

Timeline

Start
2020-04-01
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil 9 Vaccine — —

Indications

human papilloma virus infection